Stock Scorecard

Stock Summary for Apogee Therapeutics Inc (APGE) - $54.05 as of 10/24/2025 7:05:28 PM EST

Total Score

3 out of 30

Safety Score

17 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for APGE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for APGE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for APGE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for APGE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for APGE (17 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for APGE

Does Apogee Therapeutics Inc. ( APGE ) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? 10/14/2025 1:55:00 PM
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million 10/10/2025 8:01:00 PM
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million - Apogee Therapeutics ( NASDAQ:APGE ) 10/10/2025 8:01:00 PM
Why Apogee Therapeutics Stock Triumphed on Thursday 10/9/2025 9:26:00 PM
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - AZZ ( NYSE:AZZ ) , Apogee Therapeutics ( NASDAQ:APGE ) 10/9/2025 12:29:00 PM
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics ( NASDAQ:APGE ) , Ambow Education Holding ( AMEX:AMBO ) 10/9/2025 9:12:00 AM
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering 10/9/2025 1:52:00 AM
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - Apogee Therapeutics ( NASDAQ:APGE ) 10/9/2025 1:52:00 AM
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering 10/9/2025 1:52:00 AM
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology ( EADV ) 2025 Congress 9/11/2025 11:30:00 AM

Financial Details for APGE

Company Overview
Ticker APGE
Company Name Apogee Therapeutics Inc
Country USA
Description Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter N/A
Next Earnings Date N/A

Stock Price History
Last Day Price 54.05
Price 4 Years Ago 0.00
Last Day Price Updated 10/24/2025 7:05:28 PM EST
Last Day Volume 515,849
Average Daily Volume 780,775
52-Week High 25.54
52-Week Low 14.19
Last Price to 52 Week Low 280.90%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE 0.00
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 0.00
Total Cash Per Share 0.00
Book Value Per Share Most Recent Quarter 0.00
Price to Book Ratio 0.00
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 0
Market Capitalization 0
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 0.00%
Reported EPS 12 Trailing Months 0.00
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.00
Net Income Twelve Trailing Months 0
Net Income Past Year 0
Net Income Prior Year 0
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 0
Total Cash Past Year 0
Total Cash Prior Year 0
Net Cash Position Most Recent Quarter 0
Net Cash Position Past Year 0
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 0
Total Stockholder Equity Prior Year 0
Total Stockholder Equity Most Recent Quarter 0

Free Cash Flow
Free Cash Flow Twelve Trailing Months N/A
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year N/A
Free Cash Flow Prior Year N/A

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 4.58
MACD Signal 3.94
20-Day Bollinger Lower Band 29.73
20-Day Bollinger Middle Band 41.57
20-Day Bollinger Upper Band 53.42
Beta 0.00
RSI 66.39
50-Day SMA 40.90
150-Day SMA 0.00
200-Day SMA 0.00

System
Modified 12/11/2023 5:53:10 PM EST